Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on CMS Proposed Rule for Changes to CLIA Personnel Requirements
-
Sign-on Letter Urging Extension of Telehealth Flexibilities
-
Joint statement from Medical Associations Opposing Legislative Interference in Healthcare
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Group Letter Opposing Section 2527(b) of the US Innovation and Competition Act (USICA)
-
Group Sign-On Letter Regarding Telehealth Extension Legislation
-
ACMG Response to RFI on NIH Genomic Data Sharing Policy